Opinion|Videos|July 16, 2024
Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.
Advertisement
Episodes in this series
- How redefining SCLC as a molecularly heterogeneous malignancy might better inform personalized treatment of its subtypes with unique therapeutic vulnerabilities.
- How the mechanism of promoter methylation levels in ctDNA subtypes contribute to “subtype switching” in relapsed SCLC.
- Potential contribution of subtype switching to treatment resistance (platinum-based chemotherapy)
- How ‘switching’ to an inflammatory phenotype might improve therapeutic response to immune checkpoint inhibitors vs other SCLC subtypes
- The variable response of SCLC subtypes to currently available therapies
- Briefly discuss significant adverse events in patients with LS-SCLC who receiveIO-based regimens and explore strategies for their mitigation and management.
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
The OncFive: Top Oncology Articles for the Week of 8/2
4
Sonrotoclax Is Active in Chinese R/R MCL Cohort of the BGB-11417-201 Trial
5